Stem Cell TV | Video / Media News

Page 1,007«..10 20..1,0061,0071,008 1,009..1,020 1,030..»

Imago BioSciences To Present Update on Phase 2 results of Bomedemstat (IMG-7289), a Lysine Specific Demethylase-1 (LSD1) Inhibitor for the Treatment…

Posted: May 26, 2020 at 8:42 pm

SOUTH SAN FRANCISCO--(BUSINESS WIRE)--Imago BioSciences, Inc. (Imago), a clinical stage biopharmaceutical company developing innovative treatments for myeloid diseases, today announced that positive Phase 2 data from its lead pipeline program bomedemstat (IMG-7289), will be presented at the Virtual Edition of the 25th EHA Annual Congress beginning June 12, 2020.

Title: A PHASE 2 STUDY OF BOMEDEMSTAT (IMG-7289), A LYSINE-SPECIFIC DEMETHYLASE-1 (LSD1) INHIBITOR, FOR THE TREATMENT OF LATER-STAGE MYELOFIBROSIS (MF)

Session Topic: 16. Myeloproliferative Neoplasms

Final Abstract Code: EP1080

The data demonstrates the potential of bomedemstat as a monotherapy in intermediate-2 and high-risk patients with myelofibrosis who have become intolerant of, or resistant to, or are ineligible for a Janus Kinase (JAK) inhibitor.

Imago is currently conducting a Phase 2 study of bomedemstat in five countries. Clinical endpoints include spleen volume reduction, reduction in total symptom scores, and improvement in circulating inflammatory cytokines, anemia, bone marrow fibrosis and blast count. For additional information, visit cliniciatrials.gov (NCT03136185).

About Bomedemstat (IMG-7289)

Bomedemstat is being evaluated in an open-label Phase 2 clinical trial for the treatment of advanced myelofibrosis (MF), a bone marrow cancer that interferes with the production of blood cells. The endpoints include spleen volume reduction and symptom improvement at 12 and 24 weeks of treatment. Bomedemstat is used as monotherapy in patients who are resistant to, intolerant of, or ineligible for a Janus Kinase (JAK) inhibitor.

Bomedemstat is a small molecule developed by Imago BioSciences that inhibits lysine-specific demethylase 1 (LSD1 or KDM1A), an enzyme shown to be vital in cancer stem/progenitor cells, particularly neoplastic bone marrow cells. In non-clinical studies, IMG-7289 demonstrated robust in vivo anti-tumor efficacy across a range of myeloid malignancies as a single agent and in combination with other chemotherapeutic agents. Bomedemstat (IMG-7289) is an investigational agent currently being evaluated in ongoing clinical trials (ClinicalTrials.gov Identifier: NCT03136185 and NCT02842827). Bomedemstat has FDA Orphan Drug and Fast Track Designation for the treatment of myelofibrosis and essential thrombocythemia, and Orphan Drug Designation for treatment of acute myeloid leukemia.

About Imago BioSciences

Imago BioSciences is a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics targeting epigenetic enzymes. Imago has developed a series of compounds that inhibit LSD1, an epigenetic enzyme critical for cancer stem cell function and differentiation. Imago is advancing the clinical development of its first LSD1 inhibitor, bomedemstat, for the treatment of myeloid neoplasms including myelofibrosis and essential thrombocythemia. Imago BioSciences is backed by leading strategic and venture investors including a fund managed by Blackstone Life Sciences, Frazier Healthcare Partners, Omega Funds, Amgen Ventures, MRL Ventures Fund, HighLight Capital, Pharmaron, Greenspring Associates and Xeraya Capital. The company is based in South San Francisco, California. To learn more, visit http://www.imagobio.com.

Go here to see the original:
Imago BioSciences To Present Update on Phase 2 results of Bomedemstat (IMG-7289), a Lysine Specific Demethylase-1 (LSD1) Inhibitor for the Treatment...

Posted in Stem Cell Treatments | Comments Off

Orthopedics – Pennsylvania Stem Cell Center

Posted: May 25, 2020 at 8:44 am

As an alternative to orthopedic surgery, patients traditionally seek treatments such as an injection of cartilage substitutes or steroids. Despite some short-term relief, steroids actually damage tissues over time and are not a viable long-term option.

Joint Osteoarthritis is the degeneration of the joint components, both cartilage and bone. Experts agree that stem cells may help in the repair of osteoarthritis in many ways, since they may act as anti-inflammatory mediators, or forming new cartilage or bone cells, by differentiation. Each individual patient will be evaluated to determine the potential success with stem cell therapy.

Patients coping with arthritis, sports injuries, tendon strains, sprained ligaments, muscle injuries and more, will be comforted to know that surgery is not the only option of treatment available to them. Faster healing as well as improved functionality both are possible with innovative, cutting- edge adult stem cell treatments.

There are breakthroughs in non-surgical treatments for people suffering from knee pain due to common injuries to the knee meniscus, ACL or MCL. If you are experiencing cartilage damage or degenerative conditions, such as osteoarthritis, traditional options for patients suffering from these conditions include

Now, there are new ways to aid in the destruction of cartilage in your knees. Results show alternatives to surgery and Stem Cell Therapy is being recommended by more scientists and doctors every week. Stem cell research offers unprecedented opportunities for developing new treatments for debilitating diseases for which there are few or no cures. Among the knee injuries and conditions that may be treated with stem cells include:

Osteoarthritis (OA) is a degenerative joint disease that can affect any joint in your body, including your hips. Over time, due to aging, trauma or other factors, the cartilage that cushions your joints starts to break down. Without cartilage, your joint bones rub together when you move. The bone-on-bone action creates pain, stiffness, and can limit your mobility. This is especially true with OA of the hip, as the hip contains large joints that carry your bodys weight with each step you take. Treatment options for hip arthritis range from lifestyle modifications to pain management, exercise programs, and even surgery.

Non-surgical stem cell injection procedures happen within a single day and may offer a viable alternative for those who are facing surgery or hip replacement. Patients are far less vulnerable to the serious risks associated with traumatic hip surgeries, such as infection and blood clots.

Our patients quickly return to normal activity following their procedure and are able to avoid the painful and lengthy rehabilitation periods that are required following hip surgery to help restore

A common sources of shoulder pain is arthritis: which is a degenerative process causing pain, swelling, stiffness, and disability. Minor shoulder issues, for example, sore muscles and a throbbing painfulness, are regular. Shoulder pain develops from ordinary wear and tear, overuse, or a damage.

At PA Stem Cell Centers, we are a leading non-surgical specialist for chronic shoulder pain and injuries from:

As ankle pain and ankle arthritis surgery alternatives, stem cell therapy may help alleviate the cause of pain with simple office injection procedure. Patients are encouraged to walk the same day, and most experience almost no down time after the procedure.

At PA Stem Cell Centers, we are a non-surgical specialists for chronic ankle pain and injuries from:

PA Stem Cell Treatment Centers offer non-surgical, stem cell treatments for patients who are suffering from wrist and hand pain or may be facing wrist or hand surgery due to ligament injury, tendonitis, bone injuries, arthritis, bursitis and other medical conditions.

If you have an injury or pain in your hand or wrist from ligament or tendon sprains or tear, or due to osteoarthritis, you may be a candidate for stem cell therapy. At PA Stem Cell Therapy, we are leading non-surgical specialist for chronic wrist and hand pain and injuries from:

Follow this link:
Orthopedics - Pennsylvania Stem Cell Center

Posted in Pennsylvania Stem Cells | Comments Off

Stem Cell Treatment Bala Cynwyd | Stem Cell Therapy …

Posted: May 25, 2020 at 8:44 am

Stem Cell Treatment in Philadelphia, PA

To treat joint and musculoskeletal system injuries, or if you suffer from chronic conditions affecting the joints or bones, there are options other than surgery to treat the issues. At World Wellness Health Institute, Dr. Daniel Lebowitz uses stem cell therapy on people living in and around Bala Cynwyd and Philadelphia, PA, who have chronic conditions and are in need of advanced treatment to heal injuries and relieve pain associated with injuries, arthritis, and other conditions.

Stem cell therapy is a cutting-edge treatment used in orthopedic injuries and other chronic conditions that affect the musculoskeletal system, such as arthritis and neck, back and joint pain. It is now a consideration for treatment instead of surgery. With stem cell therapy, many patients regain full function of the treated area without a lengthy recovery period, unlike with surgery. This type of stem cell therapy is FDA approved and takes stem cells from the patients own adipose tissue. This tissue (fat tissue) is rich in stem cells, primarily mesenchymalstem cells.

Stem cell injections are used primarily to relieve pain in the joints as they provide the following benefits:

With stem cell therapy, fat is harvested in a process called lipoaspiration. The targeted area is numbed with a local anesthetic, then a small needle just a tad larger than a hypodermic needle is injected into the skin to remove about 10 to 20ccs of adipose tissue (fat). Once the fat is removed, it is run through another process called sterile gravity method and combined with high-density PRP (platelet-rich plasma) and injected into the site where the pain occurs. Stem cells stimulate the healing process providing several functions. They can differentiate or even change into the type of cells needed, whether its a ligament, tendon, bone or cartilage, at the injection site to start healing. We prescribe oral anti-anxiety medicine and pain medicines that you can take prior to the procedure. If necessary, Dr. Lebowitz may use local anesthetic to numb the injection sites. You typically need only one treatment but, if necessary, a follow-up treatment may be performed several weeks later.

Much of the preparation for stem cell therapy involves determining if the patient is a good candidate for this type of treatment. It is necessary to stop taking any medications and/or supplements that may thin the blood at least one week prior to the treatment, as well as avoid smoking.

Stem cell therapy treatment is not a painful procedure, as oral pain relievers and local anesthetics are used to numb the treatment areas. It is okay to return to work immediately after the procedure, as well as participate in any activities. Most patients notice improvement after two weeks and continue to experience improvement over the next few months following the treatment.

Stem cell therapy is a relatively new procedure and varies in cost depending on the area to be treated, how many treatments may be required and if it is done at the same time another treatment is performed. We can discuss the cost with you during your consultation, in addition to going over our payment options. We do offerfinancingthrough CareCredit.

If you suffer from osteoarthritis or an injury to the knee, back, neck or other joint, stem cell therapy may be right for you. Stem cell therapy is an alternative to invasive surgery when the injured area is not fully collapsed.

During your consultation to determine if you are a candidate for stem cell therapy, it is necessary for Dr. Lebowitz to examine and evaluate the area of your pain, as well as determine the root cause of the pain. Additionally, he will go over your current health, medical history, and lifestyle in terms of diet, exercise, and more. If you have any questions, he answers them in detail so that you fully understand the treatment plan.

If you are experiencing pain in any joint or other part of the musculoskeletal system as a result of an injury or chronic health condition, stem cell therapy offered at World Wellness Health Institute may be the solution. Dr. Daniel Lebowitz offers several treatments for musculoskeletal therapy to residents in Bala Cynwyd, Philadelphia and the surrounding areas of Pennsylvania.Contact ustoday!*Individual results may vary

Read the original post:
Stem Cell Treatment Bala Cynwyd | Stem Cell Therapy ...

Posted in Pennsylvania Stem Cells | Comments Off

Commentary: Kentucky’s research universities UK and UofL answering the call now and for the future – User-generated content

Posted: May 24, 2020 at 12:48 am

By Neeli Bendapudi and Eli Capilouto

When the COVID-19 pandemic hit the Commonwealth this spring, Kentuckys research universities the University of Kentucky and the University of Louisville answered the call.

Local and state leaders turned to us to lead the way in identifying and treating patients, addressing shortages in testing and protective equipment and conducting research close to home to aggressively attack a global health crisis.

We quickly began offering tests for health care workers and Kentuckys sickest patients. Our hospitals dedicated clinicians and caregivers to this fight, and we supported other hospitals by rapidly processing their tests as well.

Neeli Bendapudi

UK set up the states first field hospital on its campus to handle potential surge of infections and established a team of researchers to focus on potential vaccines and therapies, one of which is about to start its first clinical trial.

UofLs Center for Excellence in Research in Infectious Diseases and its Center for Predictive Medicine, as part of the national CDC network, are testing potential vaccines and treatments to stop COVID in its tracks. And UofL researchers have developed a technology that appears to block the novel coronavirus from infecting human cells.

Under unprecedented conditions, we are taking unprecedented steps to help and heal, protect and provide solutions.

But theres another important way we are leading, too. Now, more than ever, the future our future will depend on highly skilled workers and deep thinkers. We will need graduates, who not only compete for jobs, but create new jobs, new ideas and new approaches to both old and new challenges.

So much in our world is still so uncertain. But the necessity of thinkers and doers who can compete and thrive in an interconnected and diverse global economy will be even more important.

In this area as well, our two universities are leading our state toward a better, brighter and more certain future.

Consider these markers and milestones of progress from our two universities from 2016 to 2019 that underscore our commitment to charting that path forward:

We increased bachelors degree annual production by 909 students, 99 percent of all bachelors degree growth among Kentuckys public universities still, and perhaps even more so in the future, the entry point into the global economy

We increased the number of STEM+H degrees awarded annually by 654 graduates, 86 percent of Kentuckys increase in areas that are, in so many ways, the foundation of economic growth

We boosted degrees awarded annually to underrepresented minorities by 273, or 60 percent of the states total growth, critical to our states ability to thrive in an increasingly diverse world.

And while the overall number of bachelors degrees awarded annually to students from low-income families dropped, UK and UofL awarded 142 more degrees annually to these students, an increase of 5.5 percent growth that signifies our commitment to all students and their families. We may be forced to separate, rather than congregate, right now. But our commitment to all students, regardless of who they are or where they come from, must be stronger and broader than ever before.

Eli Capilouto

None of us knows what that will look like. But we do know what that world will require students with varied backgrounds and skills, comfortable with grappling with complex ideas and solutions more often found at the intersection of disciplines.

We are seeking and finding solutions at the cellular level to community challenges. With a deep bench of supportive world-class teachers and researchers, we will be prepared for what lies ahead. And we are poised to prepare young students with fertile minds and boundless potential to lead us.

While the COVID-19 pandemic has, for the moment, taken away their commencement ceremonies planned for this past weekend, nearly 10,000 degrees will have been awarded from the University of Louisville and the University of Kentucky this year.

These graduates will be our teachers, our health care providers, our engineers and our artists. They will build companies, invest in their communities and lead our Commonwealth through public service.

Long after our current short-term crisis has dissipated, these graduates will push Kentucky toward a brighter future. They will be prepared to tackle and solve the next pandemic and the next global crisis.

And they, too, will look to our research universities the University of Kentucky and the University of Louisville to continue to lead the way.

Eli Capilouto is president of the University of Kentucky. Neeli Bendapudi is the president of the University of Louisville.

Link:
Commentary: Kentucky's research universities UK and UofL answering the call now and for the future - User-generated content

Posted in Kentucky Stem Cells | Comments Off

Covid 19 Pandemic: STEM CELL BANKING Market 2020 Statistics and Research Analysis Released in Latest Report – 3rd Watch News

Posted: May 24, 2020 at 12:47 am

STEM CELL BANKING Players/Suppliers Profiles and Sales Data:Company, Company Basic Information, Manufacturing Base and Competitors, Product Category, Application and Specification with Sales, Revenue, Price and Gross Margin, Main Business/Business Overview.

The report presents a highly comprehensive and accurate research study on the globalSTEM CELL BANKING market. It offers PESTLE analysis, qualitative and quantitative analysis, Porters Five Forces analysis, and absolute dollar opportunity analysis to help players improve their business strategies. It also sheds light on critical STEM CELL BANKING Marketdynamics such as trends and opportunities, drivers, restraints, and challenges to help market participants stay informed and cement a strong position in the industry. With competitive landscape analysis, the authors of the report have made a brilliant attempt to help readers understand important business tactics that leading companies use to maintainSTEM CELL BANKING market sustainability.

Download Premium Sample Copy Of This Report:Download FREE Sample PDF!

Global STEM CELL BANKING Market to reach USD 11.2 billion by 2025.

Global STEM CELL BANKING Market valued approximately USD 5.4 billion in 2016 is anticipated to grow with a healthy growth rate of more than 8.4% over the forecast period 2017-2025. Global Rise in number of births and increase in R&D activities in regards with applications of stem cells, and surge in prevalence of fatal chronic diseases are owing towards a driving force for the growth of the market. The growth in GDP & disposable income is projected to help in increasing the number of stem cell units stored, which in turn boosts the market growth.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Application

oSample Collection & Transportation

oSample Processing

oSample Analysis

oSample Preservation & Storage

By Regions:

oNorth America

oU.S.

oCanada

oEurope

oUK

oGermany

oAsia Pacific

oChina

oIndia

oJapan

oRest of the World

Furthermore, years considered for the study are as follows:

Historical year 2015

Base year 2016

Forecast period 2017 to 2025

Some of the key manufacturers involved in the market are. Cord Blood Registry, ViaCord, Cryo-Cell, China Cord Blood Corporation, Cryo-Save, New York Cord Blood Program, Cord Vida, Americold, CryoHoldco, and Vita34. Other prominent players in the value chain include Caladrius Biosciences, Cryoviva, Smart Cells International Ltd., Stemade Biotech, Cytori Therapeutics, Cellular Dynamics International, PerkinElmer, and Reelabs Acquisitions and effective mergers are some of the strategies adopted by the key manufacturers. New product launches and continuous technological innovations are the key strategies adopted by the major players.

Target Audience of the Global STEM CELL BANKING in Market Study:

oKey Consulting Companies & Advisors

oLarge, medium-sized, and small enterprises

oVenture capitalists

oValue-Added Resellers (VARs)

oThird-party knowledge providers

oInvestment bankers

oInvestors

Have Any Query Or Specific Requirement?Ask Our Industry Experts!

Table of Contents:

Study Coverage:It includes study objectives, years considered for the research study, growth rate and STEM CELL BANKING market size of type and application segments, key manufacturers covered, product scope, and highlights of segmental analysis.

Executive Summary:In this section, the report focuses on analysis of macroscopic indicators, market issues, drivers, and trends, competitive landscape, CAGR of the global STEM CELL BANKING market, and global production. Under the global production chapter, the authors of the report have included market pricing and trends, global capacity, global production, and global revenue forecasts.

STEM CELL BANKING Market Size by Manufacturer: Here, the report concentrates on revenue and production shares of manufacturers for all the years of the forecast period. It also focuses on price by manufacturer and expansion plans and mergers and acquisitions of companies.

Production by Region:It shows how the revenue and production in the global market are distributed among different regions. Each regional market is extensively studied here on the basis of import and export, key players, revenue, and production.

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

Top Trending Reports:

https://brandessenceresearch.com/medical-device/sterile-medical-packaging-market-size

https://brandessenceresearch.com/medical-device/cannula-market-size

Posted in New York Stem Cells | Comments Off

Ontario Announces First Phase of Research Projects to Fight COVID-19 – Government of Ontario News

Posted: May 24, 2020 at 12:47 am

Ontario Announces First Phase of Research Projects to Fight COVID-19Ontario-Based Solutions Contribute to the Global Effort against the Outbreak

Ontario is funding the following research on preventing, detecting and treating COVID-19. These projects focus on important areas of research, including vaccine development, diagnostics, drug trials and development, and social sciences.

A Randomized Open-Label Trial of CONvalescent Plasma for Hospitalized Adults with Acute COVID-19 Respiratory Illness (CONCOR-1)Donald Arnold, Principal InvestigatorMcMaster University

CONCOR-1 is a clinical trial that will collect blood plasma from individuals who have recovered from COVID-19, known as COVID-19 convalescent plasma. Convalescent plasma contains COVID-19 antibodies, proteins that help fight the virus. Convalescent plasma will be injected into patients currently fighting the infection, to test whether this is an effective treatment for the virus. This clinical trial will enrol patients 16 years of age and older admitted to hospital with COVID-19 and who require supplemental oxygen for respiratory illness.

Partners include 60 hospitals across Canada and three hospitals in New York City, the Canadian Blood Services and Hma-Qubec and the New York Blood Center.

Research and Deployment of Rapid High-Throughput Diagnostic Testing for COVID-19Marek Smieja, Principal InvestigatorSt Joseph's Healthcare Hamilton

This project will increase Ontario's COVID-19 testing capacity by deploying robotic liquid handling technology, specimen pooling, and efficient sample preparation, while reducing biological risk and ensuring reliable results. The Disease Diagnostics & Development group in the Research Institute of St Joe's Hamilton (RSJH) is collaborating with the Hamilton Regional Laboratory Medicine Program (HRLMP) and other clinical laboratories across the province to quickly develop, validate, and deliver high-throughput, COVID-19 testing, with the goal of testing up to 6,000 samples per lab daily.

Assay Development for SARS-CoV-2 Sero-SurveillanceJennifer Gommerman, Principal InvestigatorUniversity of Toronto

This study will provide a better understanding of the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19. This approach aims to measure the level and/or types of antibodies induced by SARS-CoV-2 infection in the blood of acute and convalescent patients. In addition, measuring these antibodies in the saliva of asymptomatic infected subjects identified through contact tracing will provide insights into what the early immune response to the virus looks like, and how this may correlate with clinical outcome. This knowledge, as well as the development of a robust serosurveillance platform, represents a powerful weapon in our fight against COVID-19.

Multivalent Antibody Scaffold to Deliver an Exceptionally Potent and Broad Antiviral Against SARS-CoV-2Jean-Philippe Julien, Principal InvestigatorThe Hospital for Sick Children

This project has the potential to develop a unique antibody-based molecule for protection and treatment against COVID-19. Molecular technology will allow these researchers to decipher the vulnerabilities of the virus with the goal of developing a potent and broad antiviral that neutralizes SARS-CoV-2 and prevents associated COVID-19 symptoms.

Developing Prophylactic Virus-Vectored Vaccines for COVID-19Byram Bridle, Leonardo Susta and Sarah Wootton (Co-Principal Investigators, University of Guelph); Darwyn Kobasa, National Microbiology Laboratory, Public Health Agency of Canada (Collaborator) University of Guelph

This research aims to develop a vaccination strategy for COVID-19. By developing avian avulavirus (AAvV-1) and adenovirus viral-vectored vaccines expressing the SARS-CoV-2 spike protein as a target antigen, researchers will test these vaccines in mice to identify a way to induce robust protective mucosal (respiratory, gastrointestinal and urogenital tract) and systemic immunity. Mucosal immunity plays a significant role in preventing pathogens from getting into the body. Systemic immunity clears any pathogens that bypass mucosal barriers. After optimization, these vaccines will be evaluated in a hamster challenge model at the National Microbiology Laboratory in Winnipeg.

The RAPID COVID Study - Application of Point-of-Care COVID-19 Testing to Optimize Patient Care, Resource Allocation and Safety for Frontline StaffDerek So, Principal InvestigatorUniversity of Ottawa Heart Institute

This study will determine the role of point-of-care testing (POC) as a tool to improve care of COVID-19 patients and conserve resources. A major obstacle facing hospitals during the COVID-19 outbreak is the inability to quickly diagnose who is infected with the virus. Delayed test results could mean that patients, who ultimately test negative, are treated for days utilising resources that could be better deployed elsewhere. An immediate diagnosis of COVID-19 among carriers could provide more expedient treatment, prevent clinical deterioration and help health care workers avoid unnecessary risk of exposure.

In collaboration with Spartan Biosciences, which has developed a novel point-of-care 45-minute bedside COVID-19 test, and a team of specialists from six centres in Ontario, this research will evaluate the efficacy of POC testing to determine when, how and to who it can be applied.

A Prospective, Observational Research Study on the Diagnosis of COVID-19 Infection from Stool Samples of Children and AdultsNikhil Pai, Jeff Pernica, Marek Smieja (Co-Principal Investigators)McMaster University

Through the development and use of a novel test to diagnose COVID-19 from stool samples, this team will assess up to 4,500 stool samples collected from outpatient clinics, emergency departments and inpatient wards across eight major Hamilton region hospitals and clinics. This work will improve COVID-19 disease detection in children and adults who lack respiratory symptoms, are asymptomatic, or are presumed to have "recovered" from past infection. The researchers hope to expand COVID-19 testing options across Canada and ultimately, better identify patients who carry high risk of community transmission than traditional respiratory testing alone.

Cellular Immuno-Therapy for COVID-19 Induced Acute Respiratory Distress Syndrome: The CIRCA-19 TrialDuncan Stewart, Principal InvestigatorOttawa Hospital Research Institute

Through a series of trials, this research will rapidly evaluate the safety and efficacy of using mesenchymal stromal/stem cells, or MSCs, to help treat patients with COVID-19 related acute respiratory distress syndrome (ARDS). Up to 25 percent of all patients admitted to hospital require admission to an intensive care unit, and as many as 40 percent develop severe difficulty breathing due to ARDS.

In total, 27 patients will undergo three sequential trials. The first trial, called the Vanguard study, is designed to quickly determine the optimal dosing strategy of MSCs derived from bone marrow to treat patients experiencing ARDS. The next two trials will use the optimal dose of cells determined by the Vanguard trial, but will administer MSCs derived from the umbilical cord, which is an abundant and readily available source.

Rapid Identification of Immunogenic and T-cell Epitopes to Enable Serologic Testing, Passive Immunotherapy, and Epitope Vaccine for COVID-19Shawn Li, Principal InvestigatorWestern University

To curb the COVID-19 outbreak caused by the SARS-CoV-2 virus, researchers are looking to solve three critical challenges as quickly as possible - detection, treatment, and vaccination. This project will address these challenges by developing a point-of-care blood test to identify infected individuals, including those without symptoms, devising strategies for the production of virus-neutralizing antibodies to treat the severely ill, and identifying viral epitopes to inform epitope-vaccine development.

The Impact of the Coronavirus Pandemic on Children with Medical Complexity Technology Dependency: A Novel Research Cohort StudyAudrey Lim, Principal InvestigatorMcMaster University

This study addresses how to effectively manage pediatric patients remotely by identifying the barriers and facilitators of virtual clinics. COVID-19 is placing strain on families of children with medical complexity, medical fragility and technology dependency. Many of these children are dependent on life sustaining technology such as tracheostomy, home mechanical ventilation, and/or enteral feeding tubes. Though accounting for less than 1 percent of all children in Ontario, this group is at increased risk of multiple and prolonged hospitalizations and poorer health outcomes. Normally, these children are seen at a hospital to address their multiple complex needs, however due to COVID-19, all in-person clinic appointments have been replaced by virtual clinics. Parental satisfaction with virtual clinic healthcare teams will also be assessed using a quality improvement tool developed for this study. This research has the potential to advance virtual medicine, beyond COVID-19.

Food Retail Environment Surveillance for Health and Economic Resiliency: FRESHER OntarioJason Gilliland, Principal InvestigatorWestern University

The Food Retail Environment Surveillance for Health & Economic Resiliency (FRESHER) project is a rapid response to the widespread closures of, and modified operating conditions for, many retail food outlets. The FRESHER project will examine the economic and social impacts of COVID-19 in Southwestern Ontario by identifying what businesses modified their operations, temporarily closed or permanently closed during the outbreak and how the outbreak has affected businesses and their employees. This study will help inform policies and programs that will maintain Ontario's food security, incentivize economic growth during the recovery period, and improve resiliency among businesses during future pandemics and emergencies.

Protective Immunity in Individuals Infected with COVID-19Ishac Nazy, Principal InvestigatorMcMaster University

The goal of this research is to determine the makeup, concentration, strength and viral properties of anti-SARS-CoV-2 antibodies to provide insights into the immune response of individuals infected with COVID-19. Working with Dr. Arnold (CONCOR-1 study on convalescent plasma therapy), this team will use samples from recovered patients to test whether antibodies exist, and if they are able to bind and neutralize the virus. This research will determine whether immunity is longstanding or if it wanes over time; and will inform researchers how immune-based treatments work to fight off the virus, including convalescent plasma or future vaccines.

Clinical Research on the Therapeutic Benefits of Annexin A5 in Severe COVID-19 PatientsClaudio Martin, Principal InvestigatorLawson Health Research Institute

There are currently no proven therapies to treat COVID-19. In the most severe cases, the disease is complicated by sepsis acute respiratory distress syndrome (ARDS), and multiorgan failure. Sepsis is a life-threatening condition caused by the body's response to an infection. While the body normally releases chemicals to fight an infection, sepsis occurs when the body's response to these chemicals is out of balance, triggering systemic inflammation that can damage multiple organs. Many critically ill COVID-19 patients develop sepsis 1-2 days before ARDS, suggesting that sepsis is a major contributor to the development of organ and respiratory failure.

This clinical trial will examine the effects of Annexin A5, in treating critically ill COVID-19 patients who develop sepsis. Annexin A5 is a human protein that has potent anti-inflammatory, anti-apoptotic (cell death prevention) and moderate anticoagulant (blood clot prevention) properties. The ultimate goal of the trial is to use Annexin A5 to treat sepsis and prevent respiratory and multi-organ failure.

Novel Coronavirus Antiviral Drug Discovery Using High-Throughput ScreeningJean-Simon Diallo, Principal InvestigatorOttawa Hospital Research Institute

Using a novel bio-sensor that detects drugs that disrupt the attachment of coronaviruses to cells, this research will test approximately 1,200 approved drugs to better understand their potential to prevent viral infection in cells and their ability to block the interaction between COVID-19 and its receptor. A second phase of this study will attempt to identify novel antivirals from a small (>220,000) molecule library.

Canada's COVID-19 Pandemic Response and Impact in Low-Income and Homeless or At-Risk for Homelessness Populations in Ottawa (Canada): A Mixed Method StudySmita Pakhale, Principal InvestigatorThe Ottawa Hospital Research Institute

Vulnerable populations face numerous social and health inequities that are exacerbated during times of crises. Lessons learned from previous public health crises suggest that inappropriate communication strategies jeopardize risk reduction for vulnerable populations. The objective of this research is to measure the impacts of COVID-19 public health emergency response efforts and communication strategies on Ottawa's low-income, homeless or at-risk for homelessness populations. The findings could help inform public health messaging strategies and pandemic approaches for vulnerable populations.

Go here to read the rest:
Ontario Announces First Phase of Research Projects to Fight COVID-19 - Government of Ontario News

Posted in New York Stem Cells | Comments Off

Inolife is going to revolutionize how we take our medicine – BNNBloomberg.ca

Posted: May 24, 2020 at 12:44 am

Many of us have traumatic memories of going to the doctor to get the flu shot or childhood vaccines when we were younger. This feeling isnt uncommon as 17 per cent of the population suers from anxiety or needle phobia. Your child self wasnt being irrational eitherneedles have proven to be a pain for the medical industry as well.

Although the transdermal patch has gained popularity over the years as an innovative way to deliver medicine into ones system, jet injectors have also made waves due to their benefits in rapid administration, improved dosing accuracy, faster response rates, better diffusion into tissues, and reduced sharps waste, according to a report by Grand View Research.

For those who dread needles, a solution is on the way, and its becoming a much more pervasive method of delivering drugs, without the associated fear. As needles become outdated, Inolife R&D is working on a method to implement needle-free injections with its pipeline of prototypes for the next generation of technology.

The point of needle-free

Inolife is an emerging specialty medical device company focused on developing and commercializing novel drug delivery technologies. The company commercializes FDA-cleared and CE approved needle-free injection systems catering to a wide range of applications. Being CE approved is particularly impressive as it means that they are conform to all health, safety and environmental concerns in Europe, which are among the strictest in the world. They have also long been focused on research and development, having acquired Dutch company, European Pharmagroup, to tap into their existing global knowledge base.

Michael Wright, CEO and President, Inolife R&D.

The need for needle-free injectors goes far beyond visits to the doctor for vaccines, and the potential market benefit is massive. Some of these applications include potential use for diabetes, dental anesthesia, vaccinations, autoimmune disease, erectile dysfunction, cancer treatments, growth hormones, cosmetics (for injections of Hyaluronic Acid and similar products), and veterinary applications.

Diabetes is especially one of the fastest-growing diseases around the globeit is estimated that 374 millionpeople are at increased risk of developing type 2 diabetes.Dr. Ricordi, M.D., and Inolifes Advisory Board member, works closely with the company on improving solutions for diabetics.

He explains his involvement, "It is my professional life mission to help people who have diabetes. Inolife's synergistic mission makes us excellent strategic partners. Their technology allows diabetes patients to inject their medication without needles, with the objective of increasing care plan compliance and improving overall outcomes.

I look forward to working with Inolife to positively impact the world through novel drug delivery system development.

Inolife is bringing to market injectors that can allow for at-home insulin injections, entirely without the usage of a needle. As Michael Wright, CEO and President of Inolife notes, Cross-contamination when handling needles is a major concern globally.

Our devices have no needles and do not perforate the skin while injecting and therefore, the risk of a needlestick injury is eliminated and when done, it does not require the same costly process for disposal as a biohazard. It can be discarded or eventually recycled.

Moreover, needles are dangerous and complicated to dispose of, providing a serious biohazard after use. Many viruses can live up to 48 hours on a needle, and special biohazard bins are needed for disposal. With no needle, these concerns vanish.

Not just in science fiction

So how exactly do you inject without a needle? While each product in the Inolife family is slightly different, they all work on the same principle. Regular needles work by puncturing the skin to deliver a pool of liquid into the tissue, but the Inolife needle-free injectors deliver the fluid just under the epidermis in the subcutaneous layer by a fine high-speed jet stream.

Because there is no needle penetrating the skin, theres a smaller chance of infection. Its also much more efficient, as the medicine spreads out evenly, rather than creating a pooling effectso in the case of being used for anesthetics, you wont get that uncomfortable situation where a dentist has to inject you multiple times in multiple places. It also has a much faster uptake. The dermal layer is what protects our body, and our body thus reacts fastest to materials spread into the first line of defense.

Inolife also carries Ino 100 which is a self-injectable that can be used for up to 50 injections per nozzle. It harbours the following characteristics as well:

The COVID-19 pandemic truly proves the importance that remote medicine is going to have in the future.

Partnerships for success

Interest in Inolife has already led to a series of partnerships, joint ventures and endorsements, as the company is searching to make a difference on a global scale. It was joint ventures with pharmaceutical companies that helped develop the key nano-powder described above. These partnerships will allow for a global supply chain to patients across the globe when larger-scale production begins.

Many of those interested in Inolife are major players in global health. For example, Pharmajet, works closely with the World Health Organization (WHO) in adapting needle-free injectors for use in vaccines. The pharmaceutical industry in general has expressed a keen interest in the technology, as it anticipates a future demand for more user-friendly devices and whats more user friendly than dropping needles?

Governments have also taken note. Israel expressed its approval of the technology, and former Mexican President and Legal Representative of Centro Fox, Vincente Fox, was so interested that he became an advisor of the company.

The full press release can be viewed here.

He explains, To Centro Fox and myself, personally, this represents a great opportunity to accomplish our plan of removing the risk of needle stick injuries and cross contamination for care givers, as well as reduce anxiety for patients. Our main driver is to think of patient comfort at the system-level as well as improve home care compliancy. We want to fundamentally change how physicians and patients interact.

He adds, Now that Inolife Sciences has shown a viable and proven business model, we are moving to partner with pharmaceutical companies to enhance their therapeutic applications and compliancy by using Inolifes current technologies. We also look into the very near future and see the positive impact the Inolife nanoparticle powder injection technology could have on the entire injection marketwe can expect a few more partnerships this year and, in the years, to come.

Inolife is also looking to partnerships to perhaps expand beyond the medicines it already envisions. Studies in collaboration with McGill University are looking to develop a cannabidiol injectable to compete with other drugs for chronic pain and inflammation.

Plans for the Future

Wright is organizing private fundraising and is getting ready to take the company into public listing, which is a crucial milestone that investors should keep an eye peeled for. While a lot of focus has been on R&D and partnerships, Wright has expressed his interest in a scalable business, selling not just the injectors but the supply of the disposable syringes and further developed nano-powder injectables.

Clinical testing is also running at full steam on many of their planned products. Inolife was founded with the intention to positively impact peoples wellbeing and it is only warming up to the task. The invention of the hypodermic needle was once a medical breakthrough. One day, however, it may end up in a museum as an outdated relic, only serving as a story to scare our children about how we used to take our medicine.

Learn more about Inolife by visiting their website here.

See how the companys technology works by watching their YouTube video below.

For more investor-related information please email Chris Brown, Global Capital Markets or Michael Wright, CEO, Inolife Sciences.

Read more from the original source:
Inolife is going to revolutionize how we take our medicine - BNNBloomberg.ca

Posted in Nano medicine | Comments Off

‘Virus Goes In, Virus Goes Out’: Advocates Call For Release Of More Low-Level Prisoners To Stem Infection Rate – Kaiser Health News

Posted: May 22, 2020 at 5:48 pm

You cannot defeat a plague or a pandemic outside of prisons if you let it run free inside the prisons, which is basically whats happening, said Van Jones, head of a criminal justice advocacy group. News on prisons is from Maine, Nevada, Maryland, California, and New York, as well.

The Hill:Advocates Call On States To Release More Inmates Amid PandemicAdvocacy groups and medical experts said Wednesday that governors should release more low-level criminals to help contain the spread of the coronavirus. The public health benefits, they argued, extend far beyond prison walls. Prisons have been a hotbed of coronavirus outbreaks since social distancing is nearly impossible given the number of shared cells and communal spaces. Theres also a severe lack of masks and gloves for inmates. (Bucchino, 5/20)

Bangor Daily News:As Maine Prisons Record 1st Case Of Coronavirus, We Need To Find It And Shut It Off NowThe Maine Department of Corrections is waiting on test results for more than 120 inmates after one tested positive at a prison in Windham, the first step in determining whether a Cumberland County correctional facility is home to the states next coronavirus outbreak. (Andrews and Ferguson, 5/20)

Las Vegas Review-Journal:Nevada Reports First Coronavirus Case Among States PrisonersThe Nevada Department of Corrections announced on Wednesday a comprehensive plan to test prisoners for the new coronavirus. Officials made the announcement shortly after the first case of a Nevada prisoner testing positive for the virus was reported. According to data from the Department of Health and Human Services, which was last updated Wednesday morning, an inmate at High Desert State Prison has tested positive for the virus. (Newberg, 5/20)

The Baltimore Sun:Maryland To Test All Detainees, Staff At Prisons And Juvenile Facilities For CoronavirusFollowing calls from prisoner advocates and employee unions, Maryland will undertake universal testing at state prisons and juvenile centers, Gov. Larry Hogan announced Wednesday. Six state prison inmates have died from the coronavirus so far, and hundreds of inmates and employees have tested positive for the virus. Juvenile facilities have also experienced outbreaks, including the Silver Oak Academy in Carroll County, where dozens of children and staff tested positive. (Wood and Jackson, 5/20)

The Guardian:'People Are Sick All Around Me': Inside The Coronavirus Catastrophe In California PrisonsMore than 3,200 prisoners in California have contracted Covid-19 and at least 16 inmates have died, in a public health catastrophe that advocates say was both predictable and preventable. Inmates and advocates told the Guardian that at six prisons and jails with rapidly escalating outbreaks, basic protocols to prevent the virus from spreading are being ignored, and that they fear imminent mass fatalities and hospitalizations. (Levin, 5/20)

CNN:Michael Cohen To Be Released Thursday And Will Serve Remaining Prison Sentence At HomePresident Donald Trump's former personal attorney Michael Cohen will be released early from prison on Thursday and is expected to serve out the remainder of his sentence at home as coronavirus continues to spread behind bars, according to a person familiar with the matter. Cohen will be released on furlough while he completes the process of being moved to home confinement, the person said. (Shortell and LeBlanc, 5/20)

Go here to read the rest:
'Virus Goes In, Virus Goes Out': Advocates Call For Release Of More Low-Level Prisoners To Stem Infection Rate - Kaiser Health News

Posted in Maryland Stem Cells | Comments Off

The Alliance for Regenerative Medicine Announces 2020 Virtual Fly-In, Connecting Sector Stakeholders with Congressional Representatives Amidst the…

Posted: May 22, 2020 at 5:46 pm

Washington, DC, May 20, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- The Alliance for Regenerative Medicine (ARM), the international advocacy organization for the cell and gene therapy and broader regenerative medicine sector, announced that it will be holding its annual Legislative Fly-In today. This event, which has been remodeled to take place virtually, enables ARM members to advocate on Capitol Hill for legislative support of gene and cellular therapies and other regenerative medicines.

More than 120 ARM members are participating in the event, making this year ARMs largest Fly-In to date. Participants will form 24 state delegations to meet with Members of Congress via video calls and teleconferencing systems. The meetings will focus onthe immense near-term potential of gene and cell therapies and the need for legislation that supports patient access to these life-saving treatments.

Specifically, Fly-In participants will be asking Members of Congress to remove legislative barriers to the adoption of value-based payment models for gene and cell therapies. These therapies, which can provide a durable and potentially curative therapeutic effect, often with only a single administration, provide a profound benefit to patients and may result incost-savings to the healthcare systemin the medium to long term. However, existing reimbursement mechanisms have difficulty absorbing the upfront cost of these therapies.

To address these challenges, ARM works with its members and policymakers to promote the adoption of innovative payment models for regenerative medicines. These models include annuities, which would allow payors to amortize the cost of therapies over a longer period of time, as well as performance-based models, which tie the payment for therapies to predetermined health outcomes.

For more information on the event or ARMs legislative goals, please contact Kaitlyn (Donaldson) Dupont atkdonaldson@alliancerm.org.

About The Alliance for Regenerative Medicine

The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory, and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors, and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 350 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visithttp://www.alliancerm.org.

Kaitlyn (Donaldson) Dupont8037278346kdonaldson@alliancerm.org

Excerpt from:
The Alliance for Regenerative Medicine Announces 2020 Virtual Fly-In, Connecting Sector Stakeholders with Congressional Representatives Amidst the...

Posted in Regenerative Medicine | Comments Off

IU team pursues breathtaking regenerative medicine advances – Fort Worth Business Press

Posted: May 22, 2020 at 5:46 pm

By SAM STALL Indianapolis Business JournalINDIANAPOLIS (AP) A dime-size nanochip developed by a world-renowned researcher who recently relocated to Indianapolis could help transform the practice of medicine. It could also turn Indianapolis into a manufacturing and research hub for radically new disease and trauma treatment techniques.

It all began in August 2018, when Chandan Sen, one of the worlds leading experts in the nascent field of regenerative medicine, moved his lab from Ohio State University to the Indiana University School of Medicine. He brought along a team of about 30 researchers and $10 million in research grants, and now serves, among a myriad of other positions, as director of the newly formed Indiana Center for Regenerative Medicine and Engineering, to which IU pledged $20 million over its first five years.IU recruited Sen away from Ohio State in part because of its desire not just to promote academic research in his field but also to help develop practical, commercial products and uses for his breakthroughs.A scientist prefers to be in the lab and keep on making more discoveries, said Sen, 53.But I thought that, unless we participate in the workforce development process and the commercialization process, I dont think that the businesspeople would be ready to do it all by themselves. Because its such a nascent field.

Its definitely new and its potential sounds like the stuff of science fiction.Regenerative medicine, as its name hints, seeks to develop methods for replacing or reinvigorating damaged human organs, cells and tissues.For instance, instead of giving a diabetic a lifetimes worth of insulin injections, some of his skin cells could be altered to produce insulin, curing him. Such techniques might also be used for everything from creating lab-grown replacement organs to, someday, regenerating severed limbs.Regenerative medicine offers a form of medicine that is neither a pill nor a device, Sen said.It is a completely new platform, where you dont necessarily depend on any given drug, but are instead modifying bodily functions.Sen and his teams signal contribution to the field is a technique theyve dubbed tissue nanotransfection, or TNT. Put simply, it uses a nanotechnology-based chip infused with a special biological cargo that, when applied to the skin and given a brief electrical charge, can convert run-of-the-mill skin cells into other cell types. Potentially, the technique could be used for everything from regrowing blood vessels in burn-damaged tissue to creating insulin-secreting cells that could cure diabetics.

Obviously, such applications are still down the road a ways. But the technology is far enough along that some products are already making it to market and investors, entrepreneurs and established companies are sniffing around for opportunities. According to the Alliance for Regenerative Medicine, more than 1,000 clinical trials worldwide are using regenerative medicine technologies.Thousands of patients are already benefiting from early commercial products, and we expect that number will grow exponentially over the next few years, said Janet Lambert, the alliances CEO.Lambert predicts that the number of approved gene therapies will double in the next one to two years. Last year, the U.S. Food and Drug Administration predicted it would be approving 10 to 20 cell and gene therapies each year by 2025.These new techniques could do more than just revolutionize medicine. They could also upend the medical industry as we know it. And the IU School of Medicine and Indianapolis could lead the way.There are really only two or three places in the country that did the kind of comprehensive work that Dr. Sens group was doing, said Anantha Shekhar, executive associate dean for research at IU School of Medicine. And they were doing it from the lab all the way to the clinic, where they were already applying those technologies in patients.

So it was very attractive to think of starting with a bang bringing a comprehensive group here and creating a new center.Instead of merely treating chronic conditions, regenerative medicine could end them, once and for all.For instance, consider a car with an oil leak. The traditional medical approach might be to live with the chronic condition by pouring in a fresh quart of oil every few days. The regenerative medicine approach would fix the leak. Its good for the car, good for the cars owner but not necessarily good for the guy who was selling all those quarts of oil.Which is why these new techniques, if they catch on, could cause turmoil in the medical industry.Because regenerative medicine has the potential to durably treat the underlying cause of disease, rather than merely ameliorating the symptoms, this technology has the potential of being extremely disruptive to the current practice of medicine, Lambert said.This has the potential to be hugely disruptive, Sen added, because so much of medicine today relies on huge industrial infrastructures to manage, not cure, chronic diseases and disabilities.

If such disruption comes to pass, the leaders of 16 Tech, a 50-acre innovation district northwest of downtown that aspires to house dozens of medical-related startups and established firms, would love to be its epicenter.The Center for Regenerative Medicine will be one of the tenants of 16 Techs first building, a $30 million, 120,000-square-foot research and office building scheduled to open in June.Regenerative medicine is probably one of the next major waves of medical innovation in the world, 16 Tech CEO Bob Coy said. To have him here doing this work gives Indianapolis and Indiana an opportunity to develop an industrial cluster in regenerative medicine.Coy believes the most momentous early step on that road was the recent establishment by Sen of masters and doctoral programs in regenerative medicine at the IU School of Medicine. Its the first degree of its type in the country, earning IU and Indianapolis the enviable status of first mover.I think, for example, of (Pittsburghs) Carnegie Mellon University, which, back in the late 1960s, created the first college of computer science in the country, Coy said. And now you know Carnegie Mellons reputation in computer science.What isnt in place yet is a state or city program to promote development of a regenerative medicine hub.

We need to start doing that, Coy said. That means putting a lot of the infrastructure in place to support startups that are based on this technology, as well as recruiting companies that want to collaborate with Dr. Sen.In spite of the lack of a coherent recruitment program, Coys phone has started to ring, thanks largely to Sens presence.There have been a few meetings Ive had with people who already have relationships with him, who, when they come to town, have reached out to meet and talk about what were doing at 16 Tech, he said.One of the first 16 Tech startups with designs on the regenerative medicine niche is Sexton Biotechnologies.The company was groomed by Cook Regentec, a division of Bloomington-based Cook Group charged with incubating and accelerating technologies for regenerative medicine and the related field of cell gene therapy.Any products that show promise are either folded into the company, turned into their own divisions or, as in Sextons case, spun off as an independent entity with Cook retaining a financial stake.

Its a measure of the newness of this field that Sextons 17 employees arent working on new medicines, but rather marketing basic tools needed to conduct research. The companys offerings include a vial for storing cell and gene products in liquid nitrogen, and a cell culture growth medium.Theres a ready market for such tailor-made gear, because, for years, researchers in the regenerative medicine field had to make do with jury-rigged equipment.What most of those companies did was repurpose things like tools from the blood banking industry, or tools from bio pharma, said Sean Werner, Sextons president.So thats why a lot of newer companies are starting to build tools explicitly for the industry, as opposed to everybody just having to cobble together stuff that was already out there.

Werner said investors recognize the momentous opportunity in regenerative medicine and are flocking to the field.Its not something you have to explain, he said. Companies and VC groups are trying to get a piece of it.What has investors and medical researchers charged up is the almost unlimited range of potential applications, from healing burns to, perhaps someday, regenerating limbs.I think it would be a huge revolution if were able to, for example, regenerate insulin-secreting cells in children who have become juvenile diabetics or have for whatever reason lost their pancreas, Shekhar said. Those are the kinds of things that will start to change the way we see certain diseases.Lambert predicted that, as the science advances, so will the business case.

While early programs focused primarily on rare genetic diseases and blood cancers, were already seeing the field expand into more common age-related neurological disorders, such as Parkinsons and Alzheimers, she said.I expect this trend to continue in the coming years, greatly increasing the number of patients poised to benefit from these therapies.Werner said regenerative medicine also is seeking advancements in manufacturing technologies that will lower the cost of product development.It all adds up to a huge opportunity the state is well-positioned to seize, Werner believes.Indiana is a perfect place for this kind of thing to really ramp up, he said. Theres no reason we cant lead the field.__Source: Indianapolis Business Journal

Read this article:
IU team pursues breathtaking regenerative medicine advances - Fort Worth Business Press